Company Profile
Bain Capital Life Sciences is a dedicated investment firm focused on driving medical innovation across the global healthcare landscape. Established in 2016, the firm leverages Bain Capital's extensive four-decade history in healthcare and life sciences investing. They partner with companies developing biopharmaceuticals, medical devices, diagnostics, and life science tools, with a core mission to address unmet medical needs and improve patient lives. The firm's investment approach encompasses various stages, including Inflection Capital, Growth Capital, Fallen Angels, and larger private equity collaborations, as well as new company formation.
The firm operates as a specialized unit within the broader Bain Capital platform, benefiting from its global reach and resources. Bain Capital Life Sciences has demonstrated significant activity since its inception, managing over $7 billion in assets as of December 31, 2025, and having made more than 70 investments globally. These investments have contributed to the initiation of over 100 clinical trials, 16 regulatory authority approvals, and the launch of numerous products, underscoring their commitment to advancing medical science.
Notable companies within their portfolio include Nuvalent, Amylyx Pharmaceuticals, SpringWorks Therapeutics, and Cerevel Therapeutics, which was notably acquired by AbbVie for $8.7 billion. The firm typically makes equity investments ranging from $25 million to $100 million per portfolio company, targeting both early-stage clinical startups and mature commercial enterprises. This flexible investment strategy allows them to support companies through critical phases of value creation, from late-stage drug development to innovative medtech firms.
The Bain Capital Life Sciences team comprises over 25 professionals, including managing directors and partners with deep industry expertise, clinical insights, and extensive experience in both public and private healthcare investing. Co-founded by Adam Koppel and Jeffrey Schwartz, the team combines rigorous, science-first diligence with strategic support to foster the growth and success of their portfolio companies. Their differentiated skillset and access to Bain Capital's global network enable them to deploy capital at scale and provide value-added guidance to companies at various stages of development.
News & Signals (0)
No linked news activity found for this company.